Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients
Standard prophylactic and therapeutic ganciclovir/VGCV dosing regimen leads to underexposure in patients with low eGFR but may be appropriate for patients with higher eGFR values. However, substantial variability in ganciclovir/VGC exposure makes it challenging to achieve efficacy targets in individuals. For this reason, therapeutic drug monitoring (TDM) should be considered. Our model can be integrated into TDM software and, alongside a TDM sample, be used for dosing guidance.
Authors
- Ondřej Slanař (ORCID: https://orcid.org/0000-0002-5357-7562)
- Eliška Dvořáčková
- Jan Havlín (ORCID: https://orcid.org/0000-0002-7667-2634)
- Danica Michaličková (ORCID: https://orcid.org/0000-0002-9690-9846)
- Tereza Kotowski
- Elke H. J. Krekels (ORCID: https://orcid.org/0000-0001-6006-1567)
- Eva Klapková (ORCID: https://orcid.org/0000-0002-9903-5662)
- Andrea Zajacová (ORCID: https://orcid.org/0000-0002-9691-2500)
- Robert Lischke (ORCID: https://orcid.org/0000-0002-0578-1833)
- Jakub Petrus
- Alžběta Dutková
Institutions
- Charles University (CZ)
- University Hospital in Motol (CZ)
- Certara (United States) (US)
- Centre for Human Drug Research (NL)
- Integra LifeSciences (United States) (US)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- Medical Principles and Practice
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1159/000548942
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00